SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending downwards as traders react to renewed tariff concerns sparked by presidential comments, triggering a broad sell-off. Community sentiment is largely bearish, with many anticipating further declines and questioning the market's recent bullish behavior. Discussions revolve around potential support levels and whether this marks the start of a more significant correction.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the market reacts to potential tariff implications and broader macroeconomic uncertainty, with community members debating its role as a safe haven asset versus a risk asset. Some traders believe a significant dip is incoming, while others see current levels as a buying opportunity before a continued uptrend. Community sentiment is mixed, with some expressing frustration and others remaining optimistic about long-term prospects.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending downwards as trade tensions escalate following renewed tariff threats against China, sparking concerns about potential impacts on technology and global supply chains. Community members are weighing whether this dip presents a buying opportunity or signals the start of a larger correction, while closely monitoring key support levels. Market participants are also assessing potential impacts from a government shutdown and upcoming bank earnings.

Safe & Green Holdings Corp. is a design and construction services company, which engages in the provision of code engineered cargo shipping containers. It operates through the following segments: Construction, Medical, Development, and Corporate and Support. The Construction Services segment includes the manufacturing of unit SG ECHO and other modules projects. The Medical segment consists of joint venture COVID-19 laboratory operations. The Development segment focuses on real property development. The Corporate and Support segment includes general corporate expenses such as the executive office, corporate finance, accounting, audit, tax, human resources, risk management, information technology, marketing, and legal groups, corporate overhead, and other items not allocated to any of the company's other segments. The company was founded on December 29, 1993 and is headquartered in Miami, FL.

Safe & Green Holdings Corp

Safe & Green Holdings is trending as traders discuss a potential short squeeze, citing the stock's low float and high short interest. Community members are actively monitoring volume and consolidation patterns, anticipating a significant price movement. The company's recent news regarding compliance and settlement of litigation seems to be adding fuel to the speculative fire.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the crypto market navigates broader uncertainty, with the potential impact of a government shutdown on ETF approvals sparking debate. The community is weighing the significance of upcoming catalysts against price consolidation and market volatility, while also considering XRP's utility in cross-border payments.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Quoin Pharmaceuticals Ltd - ADR

QNRX is trending due to a recently announced private placement for up to $104.5M, which the community believes could trigger a short squeeze given the stock's low float. Traders are actively discussing potential price targets and watching for continued momentum, drawing comparisons to other recent high-flying low float stocks. However, some caution is present, referencing the risk for potential dilution.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is surging with community members expressing strong bullish sentiment and urging each other to "RAGE HARDER." The community is focused on its memetic potential and the upcoming moonshot listing. Talk centers around community support and those who have held, rather than sold, their positions.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as the stock reached new all-time highs, with the community discussing whether the AI bubble is sustainable and if the stock is overvalued. Some traders are pointing to President Trump's comments regarding potential tariffs on Chinese goods as a possible catalyst for a pullback, while others see any dip as a buying opportunity. Discussions also include potential impacts on the broader market and related sectors.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is trending amid discussions about its significance as a domestic antimony producer and potential beneficiary of government initiatives related to critical minerals. Community members are highlighting the company's existing contracts, expansion plans, and the potential for increased demand due to geopolitical factors and supply chain concerns. There is also speculation around government funding and future price targets.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending due to a mix of factors, including analyst upgrades citing its AI cloud potential and speculation around partnerships. Community discussions revolve around whether to buy the dip after recent volatility, especially with concerns about potential profit-taking. Some traders are monitoring for news from China as the market reopens following a holiday.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enanta Pharmaceuticals (ENTA) on Monday announced that its mid-stage trial evaluating the efficacy and safety of Zelicapavir in outpatient adults with acute Respiratory Syncytial Virus (RSV) infection who are at high risk of complications failed to meet the primary endpoint.Shares of the company, however, rose 58% by Monday afternoon. Notably, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-positive-topline-results-its">stated</a> that a clinically meaningful improvement in time to complete resolution of all 13 RSV symptoms was observed for Zelicapavir compared to placebo, with a benefit of 2.2 days for the overall efficacy population and 6.7 days for patients with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), or aged 75 and older.A lower hospitalization rate was observed for patients treated with Zelicapavir compared to placebo, and Zelicapavir demonstrated a robust antiviral effect, it added.The study, however, failed in its primary endpoint of lowering the time to resolution of lower respiratory tract disease symptoms to mild. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ENTA">ENTA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_1_22_50_PM_png_995d6b1542.webp" alt="ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="576" height="65"><figcaption>ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user cheered the rally.<stembedurl>https://stocktwits.com/JL_TradeZ/message/630342393</stembedurl>Another noted that though the trial missed the primary endpoint, the rest of the data “looks great.”<stembedurl>https://stocktwits.com/heyupikachu1821/message/630357384</stembedurl>Enanta said on Monday that Zelicapavir demonstrated a favorable safety profile in the trial and was well-tolerated. The goal of the study was to inform the design of a late-stage trial, including populations and endpoints, and no adverse events led to treatment discontinuation or study withdrawal in the Zelicapavir group.“We believe the totality of these data provides strong rationale for further clinical advancement of zelicapavir. Importantly, we identified multiple potential registrational endpoints for a Phase 3 trial,” said Chief Medical Officer Scott T. Rottinghaus.RSV is a common respiratory virus that infects the lungs and respiratory tract. Older adults are at significantly increased risk of severe illness due to the natural weakening of the immune system with age.ENTA stock has more than doubled this year and gained by about 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kala-bio-stock-plunges-after-experimental-drug-fails-study/chDuP3wR3Ja">Kala Bio Stock Just Plunged 89% Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, capsules are seen in a hand dressed in a medical glove with the Enanta Pharmaceuticals logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update

The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.

Equity

The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.


Larimar Therapeutics, Inc. (LRMR) on Monday announced positive data from an ongoing long-term open-label study evaluating daily subcutaneous injections of Nomlabofusp in participants with Friedreich’s Ataxia.Friedreich's Ataxia (FA) is a rare, inherited disorder causing progressive damage to the nervous system, leading to symptoms like poor coordination, difficulty walking, and sensory loss, as well as heart disease and scoliosis. It is caused by a mutation in the FXN gene, resulting in a deficiency of the mitochondrial protein frataxin.In the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/29/3157570/0/en/Larimar-Therapeutics-Announces-Positive-Data-from-Ongoing-Long-term-Open-Label-Study-and-Updates-to-Nomlabofusp-Program-for-Friedreich-s-Ataxia.html">study,</a> an increase in skin frataxin (FXN) levels was observed with short- and long-term daily Nomlabofusp. All ten participants with data at six months achieved skin FXN levels over 50% of median levels in healthy volunteers, the company stated. It added that consistent directional improvement across multiple clinical outcomes was also observed after a year of Nomlabofusp treatment.“These new data, as well as the improvement in abnormal lipid profiles observed in prior completed studies, provide support that nomlabofusp increases FXN in patients with FA and that the strategy of FXN replacement has the potential to result in a clinical benefit,” said CEO Carole Ben-Maimon.Shares of the company tumbled 47% in the pre-market session after the company reported that anaphylaxis, or a severe allergic reaction, was observed in seven participants in the open-label study, and they were subsequently withdrawn from the study. Most instances of anaphylaxis occurred on the initial day of administration and most within the first six weeks of dosing, it noted.Other discontinuations in the study included three cases of generalized urticaria, one seizure, one vasovagal event, and two non-treatment-related discontinuations, it said.The company said that it consulted experts and decided to modify its starting dose regimen after the two most recent cases of anaphylaxis. The U.S. Food and Drug Administration has agreed with the approach, the company said. Larimar is looking to submit an application for approval of Nomlabofusp to the FDA in the second quarter of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LRMR">LRMR stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.LRMR stock is down by 2% this year and by 42% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study

The company said that anaphylaxis or a severe allergic reaction was reported in seven participants in the open-label study evaluating Nomlabofusp in participants with Friedreich’s ataxia. 

Harrow (HROW) announced on Friday that it has entered into an agreement to acquire privately held Melt Pharmaceuticals for an undisclosed price.While Harrow is a provider of ophthalmic disease management solutions, Melt Pharmaceuticals is focused on developing non-opioid therapies for sedation during medical procedures. Melt was spun out of Harrow in January 2019.The acquisition will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.harrow.com/news-releases/news-release-details/harrow-acquire-melt-pharmaceuticals">include</a> Melt’s lead investigational therapy, MELT-300, a sublingually delivered formulation of a fixed dose of Midazolam (3mg) and Ketamine (50mg) designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration.Shares of Harrow jumped 4% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HROW">HROW stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.MELT-300 was found to be statistically superior to both sublingual Midazolam alone and placebo in providing successful procedural sedation in a late-stage study. A recently completed cardiac safety study also indicated that MELT-300 did not alter normal heart rhythm, supporting the therapy’s safety profile. Harrow now plans to submit a new drug application to the U.S. Food and Drug Administration for the sedative in 2027, and is eyeing a commercial launch in the U.S. in 2028.If the FDA approves MELT-300, the company intends to discontinue the MKO Melt sedation product, marketed through its ImprimisRx subsidiary, for cataract surgeries. The company also sees potential for MELT-300 to be used in other procedures, including claustrophobia during MRIs, sedation for colonoscopies, dental procedures, gastroenterology procedures, and other interventions.The closing of the merger transaction, however, is subject to customary closing conditions, including approval by Melt shareholders, Harrow added.HROW stock is up 43% this year and by about 9% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/costco-draws-mixed-reactions-from-wall-street-despite-q4-beat-here-is-why/chDVjZGR3eX">Costco Draws Mixed Reactions From Wall Street Despite Q4 Beat: Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration. 

Shares of Rambus, Inc. (<a class="mention" data-mention="$RMBS" data-symbol-id="RMBS" href="https://stocktwits.com/symbol/RMBS" target="_blank">$RMBS</a>), a provider of Double Data Rate (DDR) memory interface chips, rose sharply early Tuesday, thanks to a positive analyst action.In a note published late-Tuesday, Baird analyst Tristan Gerra initiated coverage of Rambus with an&nbsp;‘Outperform’ rating and a $90 price target, which suggests scope for about 58% upside potential.The analyst noted that Rambus’ technology and IP is central to the artificial intelligence (AI)-driven performance increase in data centers. "Rambus is at the center of our 2025 semiconductor investment themes, which include AI memory, processors and optical systems," he said.&nbsp;Rambus has over 75% revenue exposure to data centers with AI becoming a major component of growth, Gerra said.&nbsp;He noted that the company is first to market with the October announcement of the "industry-first complete memory interface chipset for Gen 5 DDR5 RDIMM and next-generation MRDIMM." These bring much higher data transfer rates, lower latency and power consumption, he added.With the lineup, the company is poised to see a significant total addressable market expansion opportunity, Gerra said.The analyst sees major license deals with leading AI chip makers into the next year due to the HBM4 controller IP it announced in September that is expected to ramp in 2026.&nbsp;Rambus is poised to see significant growth, content increase, and share gains ahead, Baird said, adding that its data center chipset opportunity is estimated at $1.5 billion.<figure class="image"><a href="https://stocktwits.com/symbol/RMBS"><img style="aspect-ratio:631/138;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/rmbs_sentiment_5078361ebc.png" alt="rmbs-sentiment.png" width="631" height="138"></a><figcaption>RMBS sentiment and message volume November 26, 2024, as of 10:30 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits platform, retailers turned ‘bullish’ (67/100) from a ‘neutral’ disposition a day ago, with message volume rising to ‘high’ level.At last check, Rambus was up 3.27% to $58.75.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Related Link:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/zoom-video-reports-beat-and-raise-q3-2025/cJIWZvyRgq">Zoom Video Stock Slumps Despite Beat-and-Raise Q3 But Retail Stays Connected</a>

Rambus shares have underperformed the broader market and the semiconductor industry this year.

Rambus Stock Powers Up After Memory Chipmaker Snags A Bullish Rating: Retail Upbeat

Rambus’ technology and IP is central to the artificial intelligence-driven performance increase in data centers, said Baird analyst Tristan Gerra.

Expectations are muted as Bath &amp; Body Works, Inc. (<a class="mention" data-mention="$BBWI" data-symbol-id="BBWI" href="https://stocktwits.com/symbol/BBWI" target="_blank">$BBWI</a>), a retailer of personal care and home fragrance products, prepares to report its third-quarter results before the market opens on Monday.Analysts, on average, expect the Columbus, Ohio-based company to report third-quarter adjusted earnings per share (EPS) of $0.47 on net sales of $1.58 billion. This compares to the year-ago numbers of $0.48 and $1.56 billion, respectively. The company guided to flat to a 2.5% increase in net sales, translating to $1.56-$1.6 billion.&nbsp;Ahead of the results, Citigroup said it expects above-consensus adjusted EPS due to a slightly stronger gross margin and lower spending, the Fly&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/news.php?symbol=BBWI">reported.</a> While conceding that the third quarter was another difficult quarter to drive sales, due to consumers remaining price-sensitive and the lack of big promotions to drive traffic, the firm said the second-half guidance is conservative enough.&nbsp;Citi believes that the fourth quarter is the best opportunity for the company to deliver upside to sales guidance this year. The firm has a Neutral rating and $35 price target for the stock. The risk/reward is skewed positive, going into the print, it said.Last week, JPMorgan analysts reduced its price target for the shares from $39 to $35.In early November, Bath &amp; Body Works announced a regular quarterly cash dividend of $0.20, payable on Dec. 6, to shareholders at the close of business on Nov. 22.The running quarter’s guidance is important, as it encompassed the holiday season. The forecast for this year’s industry-wide holiday sales is bright, with Bain &amp; Company<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bain.com/insights/2024-holiday-shopping-inside-latest-retail-sales-snap-chart/"> noting</a> a 5.4% year-on-year increase in October compared to September's 3.1% growth.&nbsp;"Santa’s sleigh has kicked into high gear for the start of the season," the firm said. Online sales grew 9.4%, in line with expectations, while in-store sales climbed a better-than-expected 4%, it added.Bath &amp; Body Works currently expects full-year net sales to fall by 2%-4%, with the 53rd week in 2023 representing a 100-basis-point headwind, and adjusted EPS of $3.02-$3.26.&nbsp;Bath &amp; Body Works shares have fallen about 27.33% for the year-to-date period.The average analysts’&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.tipranks.com/stocks/bbwi/forecast">price target&nbsp;</a>for Bath &amp; Body Works stock is $41.20, suggesting roughly 34% upside potential.<figure class="image"><a href="https://stocktwits.com/symbol/BBWI"><img style="aspect-ratio:637/130;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/bbwi_sentiment_064b8def79.png" alt="bbwi-sentiment.png" width="637" height="130"></a><figcaption>BBWI sentiment and message volume November 24, 2024, as of 9:40 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail sentiment was ‘neutral’ (49/100), a deterioration from the ‘bullish’ mood that prevailed a day ago, while message volume was ‘normal.’The stock ended Friday’s session up 0.52% at $30.71.For updates and corrections email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/govx-siga-ebs-cmrx-stocks-gain-who-declares-who-public-health-emergency/cJId4JgRge">GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks</a>

The holiday quarter got off to a promising start, with a strong October, going by Bain & Co.’s estimates

Bath & Body Works Analyst Cautious Ahead Of Q3 Print: Retail Sentiment Deflates

Price-sensitive consumers and a lack of big promotional drive dampen outlook for Bath & Body Works’ third quarter, Citi said.

Shares of Anavex Life Sciences Corp. ($AVXL) defied the broader market weakness and rallied on Thursday following a clinical trial readout.New York-based Anavex announced new data from the Phase 2b/3 study of its investigational drug candidate blarcamesin, administered as an once-daily oral formulation, demonstrating pre-specified clinical efficacy in people with early Alzheimer’s disease.&nbsp;The drug candidate, codenamed ANAVEX 2-73 worked through upstream activation of SIGMAR1, which is an integral membrane protein.Analysis of Phase 2b/3 data showed that over 48 weeks, blarcamesine&nbsp;significantly slowed clinical progression by 36.3% in the primary endpoint - Alzheimer’s Disease Assessment Scale-Cognitive 13-item, or ADAS-Cog13, scale, in the intention-to-treat&nbsp;analysis, the neurology-focused small-cap biopharma said.&nbsp;Juan Carlos Lopez-Talavera, Head of R&amp;D at Anavex, said, “The advantage of blarcamesine is that it is a small oral molecule that exerts clinical benefits on cognition and neurodegeneration and could be appealing because of its route of administration and good comparative safety profile.”The company said it is on track for regulatory submission of blarcamesine in Europe in the fourth quarter.The data was presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held in Madrid, Spain.Retail sentiment&nbsp;on Stocktwits has brightened following the data release,&nbsp;making&nbsp;Anavex stock the sixth-most trending&nbsp;ticker on Stocktwits.<figure class="image"><a href="https://stocktwits.com/symbol/AVXL"><img style="aspect-ratio:627/142;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/avxl_sentiment_b45388096b.png" alt="avxl-sentiment.png" width="627" height="142"></a><figcaption>AVXL sentiment and message volume October 31, 2024, as of 2:45 am ET | Source:&nbsp;Stocktwits</figcaption></figure>The&nbsp;sentiment meter trended in the “extremely bullish” (95/100)&nbsp;territory, improving from a “neutral” position a day ago, with message volume spiking to “extremely high.”One Stocktwits user&nbsp;sees scope for further upside in the near term. While noting that the short interest in the stock is 21%,&nbsp;the user said a short squeeze-fueled rally could materialize if the European Medicines Agency accepts the regulatory application for&nbsp;blarcamesine.<stembedurl>https://stocktwits.com/badprecog/message/590798832</stembedurl>As of 2:45 pm ET, Anavex shares rallied 16.29% to $6.64, having pulled back from an intraday high of $7.37. The stock has crossed the $7 threshold for the first time this year.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-to-report-q4-results-after-the-closing-bell-on-thursday/cJ2C2TSRBB">Apple Stock Slips Ahead Of Q4 Results As Analyst Loses Sleep Over Guidance: Retail Mood Stays Sour</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

Anavex plans to file regulatory application for its Alzheimer's drug candidate in Europe.

Anavex Life Sciences Stock Spikes On Late-Stage Alzheimer’s Drug Trial Data, Retail Mood Upbeat

Anavex' once-daily drug candidate demonstrated pre-specified clinical efficacy in people with early Alzheimer’s disease. 

Shares of telehealth company Hims &amp; Hers Health Inc. (<a class="mention" data-mention="$HIMS" data-symbol-id="HIMS" href="https://stocktwits.com/symbol/HIMS" target="_blank">$HIMS</a>) fell over 8% pre-market on Thursday following a key update from the federal government on weight-loss drug supply.Late Wednesday, the U.S. Food and Drug Administration <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize">announced</a> that Eli Lilly’s popular weight-loss and diabetes drugs, Mounjaro and Zepbound, are no longer in shortage after a two-year period where supply couldn’t meet skyrocketing demand.Both medications, which trigger the hormone GLP-1 to help curb appetite, are now available to meet projected national needs, according to the agency.Investors worry that the update could pose a headwind for telehealth companies like Hims &amp; Hers, which have capitalized on the shortages by offering compounded versions of GLP-1 drugs.These alternatives, produced by FDA-registered outsourcing facilities, are sold to customers unable to access originals such as Novo Nordisk’s (NVO) Wegovy or Lilly’s Zepbound.Under U.S. law, telehealth platforms are only allowed to manufacture these copycat drugs when the branded originals are in short supply.<figure class="image"><a href="https://stocktwits.com/symbol/HIMS"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/HIMS_sentiment_and_message_volume_Oct_3_pre_market_bdee8c8ba8.png" alt="HIMS sentiment and message volume Oct 3 pre-market" width="1314" height="320"></a><figcaption>HIMS sentiment and message volume Oct 3 pre-market</figcaption></figure>Still, retail sentiment for Hims &amp; Hers remained resilient on Stocktwits, where the ticker held a ‘bullish’ score (74/100) early Thursday.“It’s going to take a while for the market to realize this is not just a semaglutide company,” wrote one user, while another pointed out that Hims &amp; Hers never sold a compounded version of Tirzepatide (Lilly’s drug).<stembedurl>https://stocktwits.com/Hkaz34/message/587849299</stembedurl><stembedurl>https://stocktwits.com/BestRegards/message/587866562</stembedurl>Citi analysts pointed out that Hims &amp; Hers won’t be directly affected by the FDA’s decision, as it compounds semaglutide, the key ingredient in Novo Nordisk’s rival weight-loss drug, which is still on the FDA’s shortage list.&nbsp;However, they cautioned that the FDA’s announcement constrains Hims &amp; Hers's future total addressable market and "portend[s] a faster-than-anticipated resolution to shortages."&nbsp;Hims &amp; Hers is best known for selling treatments like hair-loss products and sexual-health medications like Viagra and Cialis.The company recently entered the weight-loss space as GLP-1 drugs gained popularity, offering compounded versions with the same active ingredient as Novo Nordisk’s Wegovy and Ozempic.In May, the company said its weight-loss business is expected to surpass $100 million in revenue by the end of 2025. This projection did not include the revenue potential of GLP-1 drugs, which could further bolster the company’s growth.Some analysts <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-slides-after-eli-lilly-zepbound-discount/c7wEdA9Rco">have noted</a> that Hims &amp; Hers is growing at over 40% annually, even without significant contributions from these drugs.HIMS stock has nearly doubled in value this year, although Thursday’s pre-market drop reflects the market’s ongoing sensitivity to developments in the GLP-1 space.Editor's note: This article was updated with Citi's note on the potential impact of the FDA's statement on Hims &amp; Hers' business and addressable market.Read next: <a href="https://stocktwits.com/news-articles/markets/equity/nkla-stock-surges-on-q3-deliveries/cJcGll6R3o">Nikola Stock Thunders Ahead After Impressive Q3 Electric Truck Deliveries, Attracts Retail Spotlight</a>For updates and corrections, email <a href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com.</a>

The move by Lilly is seen as a significant challenge to GLP-1 compounders, including Hims & Hers, which recently entered the weight-loss drug market. 

Hims & Hers Stock Slides After FDA Says Eli Lilly’s Weight-Loss Drug No Longer In Shortage, But Retail Shrugs Off Worries

Under U.S. law, telehealth platforms are only allowed to manufacture copycat weight-loss drugs when the branded originals are in short supply. 

Shares of telehealth company Hims &amp; Hers Health Inc. (HIMS) fell over 5% on Tuesday following <a href="https://stocktwits.com/news/markets/equity/eli-lilly-releases-single-dose-vials-of-weight-loss-drug-zepbound/c7wEcbCRcn">news</a> that Eli Lilly &amp; Co. (LLY) is now selling single-dose vials of its popular weight-loss drug Zepbound at a steep discount.Lilly’s Zepbound vials, priced at $399 per month, represent a 50% or greater discount compared to other incretin or GLP-1 medicines for obesity, as the company attempts to address ongoing supply shortages.The move by Lilly is seen as a significant challenge to GLP-1 compounders, including Hims &amp; Hers, which recently entered the weight-loss drug market.Citi analyst Daniel Grosslight described Lilly’s pricing strategy as a "shot across the bow" for compounders, emphasizing the company's efforts to protect patients from counterfeit or unsafe knock-off versions of the drug.Despite the potential threat from Lilly, analysts remain cautiously optimistic about Hims &amp; Hers' prospects. Needham, which recently initiated coverage of HIMS with a ‘Buy’ rating and a $24 price target, acknowledged the increased volatility associated with the company’s GLP-1 offerings but believes that the impact will ultimately be more positive than negative.Needham said Hims &amp; Hers continues to grow at over 40% annually, even without significant contributions from GLP-1 drugs, boasting over $1 billion in revenue with multiple growth opportunities.<figure class="image"><a href="https://stocktwits.com/symbol/HIMS"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/HIMS_sentiment_and_message_volume_Aug_27_11a0edd9ae.png" alt="HIMS sentiment and message volume Aug 27.png" width="1310" height="316"></a><figcaption>HIMS sentiment and message volume Aug 27</figcaption></figure>On Stocktwits, retail sentiment for HIMS shifted from ‘bearish’ to ‘neutral’ (53/100), with several watchers expressing confidence in the company's long-term growth potential beyond the GLP-1 segment.<stembedurl>https://stocktwits.com/Robinhoodboys/message/584240092</stembedurl>One user pointed out that GLP-1 drugs represent less than 10% of Hims &amp; Hers’ entire drug portfolio, highlighting the company’s diversified product mix.<stembedurl>https://stocktwits.com/ThinkVest/message/584245377</stembedurl>Earlier this month, Hims revealed it was set to buy a U.S.-based compounding pharmacy for approximately $31 million, in line with its strategy of offering copycat versions of popular weight-loss drugs, including those from Novo Nordisk (NVO).Despite the challenges posed by larger competitors like Lilly, Hims &amp; Hers’ strong Q2 performance, which exceeded Wall Street expectations, showed the beat was driven by surging demand for its weight-loss medicines.The company also raised its 2024 sales forecast to a range of $1.37 billion to $1.40 billion (from an earlier guidance of $1.20 billion to $1.23 billion), signaling confidence in its continued growth and market presence.Read Next: <a href="https://stocktwits.com/news/markets/equity/cava-stock-falls-after-key-insiders-sell-shares/c7wEcRaRcF">Cava Stock Plunges As CEO, Key Stakeholders Offload Shares Amid Record Highs: Is Retail Mood Souring?</a>&nbsp;&nbsp; &nbsp;

HIMS Stock Slides After Eli Lilly’s Discounted Single-Dose Zepbound Offering: Retail Investors Unfazed

Wall Street remains cautiously optimistic about Hims & Hers' prospects, with one analyst saying it continues to grow at over 40% annually even without significant contributions from GLP-1 drugs

Despite the potential threat from Lilly, Wall Street remains cautiously optimistic about Hims & Hers' prospects, with one analyst saying it continues to grow at over 40% annually even without significant contributions from GLP-1 drugs


Shares of fast-casual Mediterranean chain Cava Group (CAVA) dropped over 8% in pre-market trading on Tuesday, after closing at a record high in the previous session. &nbsp;The decline comes in response to an SEC filing that revealed key shareholders and top executives have been offloading significant portions of their holdings in the company.Artal International S.C.A., a 10% stakeholder in Cava, sold six million shares of the firm worth $732 million. This sale comes over and above the 5.55 million shares that Artal already sold in the past three months.The move by Artal signals a potential shift in sentiment among early investors who have benefited from Cava’s meteoric rise since its IPO.<stembedurl>https://stocktwits.com/HeisenbergCap/message/584223663</stembedurl>Cava's leadership has also been cashing in on the company’s recent success. CEO Brett Schulman exercised his option to sell 201,504 shares, netting $24.9 million. Founder and Chief Concept Officer Ted Xenohristos also sold 98,490 shares, earning $12.4 million. Furthermore, three other directors collectively sold 11,500 shares.<stembedurl>https://stocktwits.com/mpier/message/584236225</stembedurl>On Stocktwits, retail sentiment stayed in the ‘neutral’ zone (52/100), with message volume surging, as watchers digested the development.<figure class="image"><a href="https://stocktwits.com/symbol/CAVA"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CAVA_sentiment_and_message_volume_Aug_27_premarket_0f309e0c1e.png" alt="CAVA sentiment and message volume Aug 27 premarket.png" width="1310" height="316"></a><figcaption>CAVA sentiment and message volume Aug 27 premarket</figcaption></figure>Cava has been a stand-out performer in the restaurant sector. Since its market debut in June 2023, the stock has soared nearly 230%, driven by a series of earnings beats, impressive same-store sales growth, and the successful launch of new menu items.Earlier this month, Cava reported better-than-expected Q2 results for 2024 and raised its full-year guidance.However, concerns about the company’s valuation have begun to surface. Cava’s price-to-earnings (P/E) ratio currently stands at an eye-popping 345.89, far exceeding that of industry giants like Chipotle Mexican Grill (53.65) and McDonald's Corp (25.26).&nbsp;Read Next: <a href="https://stocktwits.com/news/markets/equity/pzza-stock-rises-on-takeover-speculation/c7w36O5RcN">Papa John’s Stock Rises, Retail Buzz Grows As Analyst Note Sparks Takeover Speculations</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;

Cava's leadership has also been cashing in on the company’s recent success. 

Cava Stock Plunges As CEO, Key Stakeholders Offload Shares Amid Record Highs: Is Retail Mood Souring?

Artal International, a 10% stakeholder in Cava, sold six million shares of the firm worth $732 million on Monday.

CAVA Stock Topples From Record High On Insider Sales: Is Retail Mood Souring?

Artal International, a 10% stakeholder in Cava, sold six million shares of the firm worth $732 million on Monday.


Shares of fast-casual Mediterranean chain CAVA Inc. (CAVA) saw the highest jump in new retail followers on Stocktwits over the past 24 hours on Thursday, despite ending the session in the red due to profit-booking.Message volume related to the stock surged more than 575% to reach ‘extremely high’ (92/100) levels, as watchers eagerly discussed the company’s Q2 results, which comfortably beat Wall Street estimates on revenue and profit.Same-store sales grew by an impressive 14.4%, exceeding most expectations, while traffic increased by 9.5% during the quarter. This suggests that the restaurant chain is reportedly outperforming many of its peers in a challenging economic environment with cost-conscious consumers.The company highlighted that its grilled steak offering provided customers with "another reason to visit Cava and come back more often." Additionally, CAVA raised its full-year outlook for same-store sales, new location openings, and adjusted profit.At least four Wall Street brokerages have raised their price targets for CAVA, with Baird setting the highest at $125—representing more than a 12% upside from current levels. However, Barclays is the only brokerage so far with a target below current levels, at $95.Despite the stock's near-9% jump before the bell on Friday, retail sentiment on Stocktwits remained 'bearish' (41/100), though it showed slight improvement from the previous day.<figure class="image"><a href="https://stocktwits.com/symbol/CAVA"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CAVA_sentiment_and_message_volume_Aug_23_premarket_c017101953.png" alt="CAVA sentiment and message volume Aug 23 premarket.png" width="1310" height="316"></a><figcaption>CAVA sentiment and message volume Aug 23 premarket</figcaption></figure>Several pessimistic observers expressed concerns about the stock’s valuation.“$CAVA very overvalued imo and fake pump so big boys can unload to bag holders (retail). Caution,” warned one user.<stembedurl>https://stocktwits.com/stockswnoiz/message/583908678</stembedurl>“$CAVA Forward P/E is 300!+. That’s crazy!,” posted another bearish user.<stembedurl>https://stocktwits.com/ShortyMcShorterson/message/583891113</stembedurl>CAVA’s current market cap stands at $11.63 billion, with its valuation having skyrocketed over 167% since its stellar market debut in June 2023.The stock’s current price-to-earnings (P/E) ratio is 400.86, which significantly exceeds that of Chipotle Mexican Grill (CMG) at 52.38 and Domino’s Pizza Inc. (DPZ) at 25.59.Wedbush Securities believes CAVA is positioned to sustain positive transaction growth and gain market share over the long term, even relative to its growth peers, adding that the stock's premium valuation would be justifiable.But on Retail Street, investors are just not able to digest these views for now.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

The company highlighted that its grilled steak offering provided customers with "another reason to visit Cava and come back more often."

CAVA Stock’s Retail Following Jumps Most After Upbeat Q2 Results, But Sentiment ‘Bearish’

The restaurant chain is reaping the rewards of its grilled steak offering, which has been hit with customers. Shares are trading at all-time highs just 14 months after going public, but retail sentiment is still repressed.

CAVA Stock’s Retail Following Jumps Most After Upbeat Q2 Results

The restaurant chain is reaping the rewards of its grilled steak offering, which has been hit with customers. Shares are trading at all-time highs just 14 months after going public, but retail sentiment is still repressed.


BlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

IWV
BlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWV News

IWVBlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF